- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Biocad Forges Ahead With Biosimilar Infliximab
Biocad, a Russia-based drug manufacturer, received approval for an infliximab biosimilar (referencing Remicade) from Russia’s Federal Drug Control Service last month. The company anticipates expanding to other markets as soon as later this year, or early 2019.
Biocad, a Russia-based drug manufacturer, received approval for an infliximab biosimilar (referencing Remicade) from Russia’s Federal Drug Control Service last month. The company anticipates expanding to other markets as soon as later this year, or early 2019.
In order to receive regulatory approval, Biocad completed international clinical studies of the infliximab biosimilar in direct comparison with the reference product. The infliximab biosimilar was investigated in treating indications of its reference, specifically ankylosing spondylitis and rheumatoid arthritis (RA).
The studies found that the therapeutic effects of the biosimilar were shown to be equivalent to the reference. In addition, the safety profiles of the 2 drugs were also similar in the long-term.
Biocad reportedly believes that India will be the first country to receive shipments of the biosimilar, where the infliximab market is valued at around $50 million for 2018.
Infliximab is the fourth monoclonal antibody biosimilar for which Biocad has gained regulatory approval. Past approvals include biosimilars of bevacizumab, trastuzumab, and rituximab. The drug maker won its patent dispute over rituximab with the reference manufacturer, Roche, last October.
Around the same time this legal win was announced, Biocad revealed intentions to enter the European market with oncological and autoimmune therapies. The company has both innovative and biosimilar products currently for sale in Europe, spanning treatments for melanoma; breast, stomach, kidney, and lung cancer; RA; psoriasis; and multiple sclerosis.
“As for the European Union countries, where the approval of biological product goes under centralized procedure through the European Medicines Agency, taking into account the need for local clinical trials, we expect to get marketing authorization for biological products in 2021,” said Dmitry Morozov, general director of Biocad.
According to a press release, the company estimates that, in 2021, its generics of oncology drugs docetaxel, paclitaxel, pemetrexed, and irinotecan will also enter the European market.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
